Consumer genetics firm 23andMe has appointed Robert Gentleman, formerly of Genentech, as its VP of computational biology.
The company recently announced it would launch a therapeutic division led by Richard Scheller, who was executive VP of research and early development at Genentech. Scheller is slated to join 23andMe at the start of April as chief science officer and the head of the therapeutics division.
Gentleman will work with Scheller employing data analytics and theoretical models to pinpoint trends that can inform drug discovery and development. Before joining 23andMe, Gentleman was senior director of bioinformatics and computational biology at Genentech. Prior to that he was head of the computational biology department at the Fred Hutchinson Cancer Research Center, as well as a professor at Harvard University, the University of Auckland, and the University of Waterloo.
The National Cancer Institute named Douglas Lowy its acting director, following the departure of Harold Varmus. Lowy has been NCI's deputy director since July 2010. A cancer researcher for 40 years, he received the National Medal of Technology and Innovation from President Obama last year for work that resulted in the development of the human papillomavirus vaccine. He is a member of the National Academy of Sciences and the Institute of Medicine of the NAS.
Former Life Technologies CEO Greg Lucier was named chairman and interim CEO of NuVasive following the resignation of Alex Lukianov. An internal investigation by the company's board found that Lukianov did not comply with NuVasive's expense reimbursement and other policies.
Lucier has been a board member of NuVasive since 2013. From 2003 to 2014 he was chairman and CEO of Life Techn before it was acquired by Thermo Fisher Scientific. Prior to Life Tech, he was a corporate officer at General Electric and an executive at GE Medical Systems.
Gerald Feldman has assumed the presidency at the American College of Medical Genetics, taking over from Gail Herman who finished her two-year term at the 2015 Annual Clinical Genetics Meeting in Salt Lake City last week.
Feldman was elected president-elect of ACMG two years ago. He is a professor of molecular medicine and genetics, pathology and pediatrics at Wayne State University School of Medicine. He directs the medical genetics residency and fellowship programs and serves as medical director of the genetic counseling graduate program.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.